Drug Profile
SC 0806
Alternative Names: heparin-activated recombinant human fibroblast growth factor 1; rhFGF1 - BioArctic; SC0806Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Swenora Biotech
- Developer BioArctic
- Class Fibroblast growth factors; Neuroprotectants
- Mechanism of Action Fibroblast growth factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Spinal cord injuries
Most Recent Events
- 18 Nov 2019 Discontinued - Phase-II for Spinal cord injuries (In adults) in Estonia, Norway, Sweden (Intrathecal)
- 13 Feb 2019 Phase-II clinical trials in Spinal cord injuries (In adults) in Sweden, Norway and Estonia (Intrathecal)
- 09 Oct 2018 BioArctic receives patent protection for a method with the medical device components in the SC 0806 for treatment of Spinal cord injuries in Europe